Your browser doesn't support javascript.
loading
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler, M; Yang, J C-H; Park, K; Kim, J-H; Bennouna, J; Chen, Y-M; Chouaid, C; De Marinis, F; Feng, J-F; Grossi, F; Kim, D-W; Liu, X; Lu, S; Strausz, J; Vinnyk, Y; Wiewrodt, R; Zhou, C; Wang, B; Chand, V K; Planchard, D.
Afiliación
  • Schuler M; West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen German Cancer Research Center, German Cancer Consortium (DKTK), Heidelberg, Germany martin.schuler@uk-essen.de.
  • Yang JC; Department of Medical Research, National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan.
  • Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
  • Kim JH; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Bennouna J; Oncologie Médicale, Institut de Cancérologie de l'Ouest, Nantes, France.
  • Chen YM; Taipei Cancer Center, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Chouaid C; Services de Pneumologie, CHI Créteil, Créteil, France.
  • De Marinis F; 1st Oncological Pulmonary Unit, San Camillo, High Specialization Hospital, Rome Thoracic Oncology Division, European Institute of Oncology, Milan, Italy.
  • Feng JF; Department of Medical Oncology, Jiangsu Province Cancer Hospital, Nanjing, China.
  • Grossi F; IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
  • Kim DW; Lung Cancer, Seoul National University Hospital, Seoul, Republic of Korea.
  • Liu X; Department of Pulmonary Oncology, Affiliated Hospital of Academy of Military Medical Science, Beijing.
  • Lu S; Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Strausz J; Department of Pulmonology, Koranyi National Institute for Pulmonology, Budapest, Hungary.
  • Vinnyk Y; Abdominal Department, Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine.
  • Wiewrodt R; Department of Medicine A, University Hospital, Münster, Germany.
  • Zhou C; Department of Oncology, Tongji University Medical School Cancer Institute, Shanghai, China.
  • Wang B; Biostatistics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield.
  • Chand VK; Clinical Development Medical Affairs-Oncology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, USA.
  • Planchard D; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
Ann Oncol ; 27(3): 417-23, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26646759
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quinazolinas / Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Carcinoma de Pulmón de Células no Pequeñas / Clorhidrato de Erlotinib / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quinazolinas / Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Carcinoma de Pulmón de Células no Pequeñas / Clorhidrato de Erlotinib / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Alemania